Generic Name: givosiran
Brand Name: Givlaari
Manufacturer: Alnylam Netherlands B.V.
Therapeutic Area: Acute hepatic porphyria (AHP) in adults
Indications: Treatment of acute hepatic porphyria (AHP) in adults
Manufacturer Requested Reimbursement Criteria1: Treatment of acute hepatic porphyria (AHP) in adults
Submission Type: Initial
NOC Status at Filing: Post NOC
Project Status: Received
Companion Diagnostics: No
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient/clinician input open||January 25, 2021|
|Call for patient/clinician input closed||March 19, 2021|
|Submission received||February 23, 2021|